Best Probiotics in Canada (2026)
October 24, 2026Iron Every Other Day Worked Just as Well: New Trial
October 26, 2026Quick Summary
Here is the short version: in a small UCLA trial, breast cancer survivors struggling with “chemo brain” took oxaloacetate, a natural energy molecule, for eight weeks — and every woman who finished said her thinking got noticeably better. Their scores moved from the impaired range into the normal range, and their fatigue eased too. The catch? There was no placebo group, so we cannot yet say the supplement caused the improvement. A proper placebo-controlled trial is coming next.
Imagine finishing cancer treatment, getting the all-clear, and then not finding the word for… that thing you use to open a door. For up to 1 in 4 breast cancer survivors, that fog does not lift when treatment ends — and until now, doctors have had almost nothing to offer for it. A tiny new trial just gave them their first real lead, and the results were so striking that the researchers themselves called them “impressive and universal.”
| Topic | What the research shows |
|---|---|
| The study | Phase 2 trial from the UCLA Health Jonsson Comprehensive Cancer Center, published in JCO Oncology Advances (2026) |
| Who took part | 18 women with early-stage breast cancer, 1 to 5 years after primary treatment |
| The dose | 500 mg of oxaloacetate, twice a day, for 8 weeks |
| The headline result | Scores for perceived cognitive impairment rose from 29.1 to 55.5 — from the impaired range into the normal range |
| The catch | No placebo group, so the improvement cannot yet be credited to the supplement itself |
| Side effects | Mostly mild stomach issues; 2 women dropped out because of them; no serious adverse events reported |
What the UCLA team actually tested
Cancer-related cognitive impairment — “chemo brain” or “brain fog” — is one of the most frustrating leftovers of breast cancer treatment. People lose words mid-sentence, forget errands, and struggle to focus on tasks that were once easy. An estimated 15% to 25% of breast cancer survivors deal with persistent thinking problems after treatment. And despite the name, chemotherapy is not the only suspect: the cancer itself, hormone therapy, inflammation, and hormonal changes may all play a role.
That is what makes this trial interesting. Led by Dr. Patricia Ganz at UCLA, the researchers recruited 18 women with early-stage breast cancer who were 1 to 5 years out from their primary treatment and still reporting serious cognitive difficulties. Most had previously received chemotherapy, and nearly 90% were on endocrine (hormone) therapy at the time. Each woman took 500 mg of oxaloacetate twice a day for eight weeks, while researchers tracked symptoms with questionnaires and standardized thinking tests.
It was a small, open-label study — everyone knew they were getting the supplement, and there was no comparison group. That matters a lot, and we will come back to it. But first, the results.
The results were almost too good — and that is the problem
Sixteen of the 18 women completed the eight weeks, and all 16 reported significant improvements in their cognitive symptoms. On the study’s main measure of perceived cognitive impairment, average scores climbed from 29.1 before treatment to 55.5 after eight weeks — moving the group from a range considered impaired into a range considered normal. Improvements showed up after four weeks and generally grew stronger by the end of treatment.
It was not just self-reported thinking, either. Participants reported less fatigue, including mental fatigue, and better physical functioning. Standardized testing also showed gains in executive function — the skills behind planning, focusing, and managing tasks — and in processing speed.
So why the caution? Without a placebo group, this trial cannot prove oxaloacetate caused any of it. Some improvement could reflect a placebo effect, natural ups and downs in symptoms, or simply the extra attention of being studied. The researchers say so themselves: further research is needed to determine whether oxaloacetate was responsible.
The follow-up is already lined up: the team has FDA approval for a randomized, placebo-controlled phase 2 trial, slated to open later in 2026. As Dr. Ganz put it, they have something that “seems to be very active and non-toxic” and need to test it in a placebo-controlled trial. Until that trial reports, this story is a promising lead — not a proven answer.
Why oxaloacetate? The energy-and-glutamate theory
Oxaloacetate is not some exotic lab invention. Your body makes it every day: it is a key intermediate in the Krebs cycle, the cellular process that turns nutrients into ATP, the energy currency your cells run on. Researchers picked it for two connected reasons.
First, cancer-related inflammation may disrupt both cellular energy production and glutamate signaling in the brain. Glutamate is a neurotransmitter that supports learning and memory, and when its signaling goes off balance, thinking can suffer. Second, oxaloacetate has been studied in animals as a “blood glutamate scavenger” — a compound that helps draw excess glutamate out of the brain by lowering glutamate levels in the blood. That mechanism is still largely animal evidence, not proof in people, but it gave the team a reason to run the trial.
What is oxaloacetate and how is it supposed to work?
Oxaloacetate (sometimes written as oxaloacetic acid) is a small molecule your body produces as part of normal energy metabolism. It sits at a crossroads of the Krebs cycle: it helps kick off the cycle that generates ATP, and it also takes part in moving glutamate around.
As a supplement, oxaloacetate is a niche, newer ingredient — not a staple like vitamin D or magnesium. It is a fragile molecule that breaks down easily outside the body, which is why supplement makers use specially stabilized forms. The idea behind taking it is to support the body’s energy production and glutamate balance. The idea is plausible, with animal research behind it, but human evidence is still early: this was one of the first human tests, and it had no placebo group.
What are the side effects of oxaloacetate?
In the UCLA trial, oxaloacetate was generally well tolerated. The most common side effects were stomach-related: indigestion, bloating, constipation, diarrhea, and nausea. Two participants stopped treatment because of stomach symptoms, and no serious adverse events were reported.
That is reassuring but limited — 18 people over eight weeks cannot reveal rare or long-term risks. Anyone in active cancer treatment should be especially careful: this trial studied survivors past their main treatment, and interactions with hormone therapy or other cancer medicines have not been studied. If you are dealing with cancer-related thinking problems, talk to your oncologist before trying any supplement for it — and never swap a prescribed treatment for a supplement.
How much oxaloacetate should you take?
The only dose with human evidence behind it in this context is the one the UCLA trial used: 500 mg twice a day, or 1,000 mg a day, for eight weeks. There is no established recommended daily dose for oxaloacetate, and no official guidance on long-term use.
More is not better here. Doubling the dose would not double the benefit — it would mostly raise the odds of stomach trouble. And because the evidence is one small trial without a placebo group, there is no dose anyone can point to and call proven. If a future placebo-controlled trial confirms the effect, dosing guidance will follow from that research, not from guesswork.
What should you look for on the label?
Oxaloacetate is a small, niche market, so shopping for it takes more care than usual. Look for the actual amount of oxaloacetate per serving, stated plainly — not buried inside a proprietary blend where you cannot tell how much you are getting. Because the molecule is fragile, look for a stabilized form and a brand that explains how it keeps the ingredient intact. The UCLA trial used a form called anhydrous enol-oxaloacetate, a stabilized version of the molecule — a useful benchmark when comparing products.
Third-party testing matters even more for a niche ingredient like this: an independent check that the capsule actually contains what the label claims. In Canada, check for a valid 8-digit NPN on the label. Any supplement legally sold in Canada should carry one, and a product without it is a red flag. Finally, be skeptical of big promises: any oxaloacetate product claiming to fix “chemo brain” is getting far ahead of the evidence, which so far amounts to one small, uncontrolled trial.
References
- Ganz, P. A., Van Dyk, K., Crespi, C. M., Petersen, L., Sedrak, M. S., & Bower, J. E. (2026). Results from a Phase II single-arm trial evaluating the safety and efficacy of anhydrous enol-oxaloacetate on improving cognitive complaints in breast cancer survivors. JCO Oncology Advances, 3(4), e2600063. https://doi.org/10.1200/OA-26-00063
- MedicalXpress. (2026, October 20). Nutritional supplement may help ease ‘brain fog’ after breast cancer treatment. https://medicalxpress.com/news/2026-10-nutritional-supplement-ease-brain-fog.html
- Breast Cancer Research Foundation. (2026, October 22). Supplement may help ease brain fog after breast cancer treatment. https://www.bcrf.org/blog/supplement-may-help-ease-brain-fog-after-breast-cancer-treatment/
- Boyko, M., Gruenbaum, S. E., Gruenbaum, B. F., Shapira, Y., & Zlotnik, A. (2014). Brain to blood glutamate scavenging as a novel therapeutic modality: A review. Journal of Neural Transmission, 121(8), 971–979. https://pmc.ncbi.nlm.nih.gov/articles/PMC4382077/
This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.
